FDA Guidance Sheds Light On Human Factor Studies For Combo Products
This article was originally published in The Gray Sheet
Executive Summary
Questions from companies and FDA reviewers about human factor design and data requirements for combination products continue to grow. In response, the agency has issued a draft guidance.
You may also be interested in...
Q&A Guidance Clarifies Human Factors Testing For Combination Products
A highly anticipated final guidance from the FDA on Human Factor Studies answers frequently asked questions about human factor studies when designing combination products.
Combination Product Human Factors Final Guidance In Clearance, OCP Says
The OCP presented its priorities for 2023 and beyond at the RAPS/AFDO Combination Products Summit on 8 November.
Companies Want New US FDA Council To Help Resolve Inter-Agency Combo Product Disputes
A range of topics were raised in feedback provided by industry groups to FDA about what the priorities should be for the agency's new Combination Products Policy Council, but addressing inter-center disagreements was a repeat concern. Also raised: misaligned communication policies; pediatric combo-product reviews; and implementation of the 21st Century Cures Act.